About
The Xinnate business plan is based on scientific resarch about the body’s own innate defence system. Xinnate will build a portfolio of pharmacetical products based on our proprietary dual-action peptide, TCP-25. The first application planned is a treatment gel for burn wounds.
Read more about our: